Back to top
more

Morphic (MORF)

(Delayed Data from NSDQ)

$28.71 USD

28.71
335,352

+0.74 (2.65%)

Updated May 2, 2024 04:00 PM ET

After-Market: $28.65 -0.06 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes Morphic (MORF) a New Buy Stock

by Zacks Equity Research

Morphic (MORF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Best Momentum Stocks to Buy for February 14th

by Zacks Equity Research

LUMN, SFST and MORF made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 14, 2023.

New Strong Buy Stocks for February 14th

by Zacks Equity Research

GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.

Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 57.2% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Morphic Holding, Inc. (MORF) Could Rally 110.28%: Here's is How to Trade

by Zacks Equity Research

The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to an 110.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Morphic Holding, Inc. (MORF) Have the Potential to Rally 92.88% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 92.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 150.17% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Morphic Holding, Inc. (MORF) points to a 150.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 160.84%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 160.8% upside potential for Morphic Holding, Inc. (MORF). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Morphic Holding, Inc. (MORF) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Morphic Holding, Inc. (MORF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Alkermes (ALKS) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Alkermes (ALKS) delivered earnings and revenue surprises of 14.58% and 7.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio

by Zacks Equity Research

Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.

Ekta Bagri headshot

Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates

by Ekta Bagri

Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.

Morphic Holding, Inc. (MORF) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -5.88% and 78.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last?

by Zacks Equity Research

Morphic Holding, Inc. (MORF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 2.50% and 46.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex (VRTX) Beats on Q3 Earnings, Ups 2022 Sales Guidance

by Zacks Equity Research

Vertex Pharmaceuticals' (VRTX) third-quarter 2022 earnings and sales beat estimates. VRTX also raises its revenue guidance for 2022. The stock rises in the after-market trading.

BioMarin (BMRN) Q3 Earnings Beat, Sales Miss, Ups Voxzogo View

by Zacks Equity Research

BioMarin Pharmaceutical's (BMRN) third-quarter 2022 earnings beat estimates, but sales slightly miss the mark.

Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook

by Zacks Equity Research

Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.

Moderna (MRNA) Gets CHMP Nod for Omicron BA.4, BA.5 Booster Jab

by Zacks Equity Research

The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.4/5 subvariants, for use in adults and adolescents aged 12 years and older.

Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension

by Zacks Equity Research

The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.

Reata (RETA) Up After FDA Scraps AdCom Meeting for NDA Filing

by Zacks Equity Research

The FDA decides not to hold an advisory committee meeting for Reata Pharmaceuticals' (RETA) regulatory filing seeking approval for omaveloxolone in Friedreich's Ataxia.

Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study

by Zacks Equity Research

Relmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve statistical significance. Shares plunge 80% following the news.